This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A summary of current and novel biomarkers and their potential stages of release in cardiogenicshock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenicshock: progression from cardiac dysfunction/stress, through to inflammation and end-organ dysfunction.
Journal of the American Heart Association, Ahead of Print. BackgroundThe effects of pharmacological therapy on cardiogenicshock (CS) survivors have not been extensively studied.
Abstract Aims Left ventricular unloading by percutaneous microaxial flow-pump devices has been shown to improve survival in patients with cardiogenicshock (CS). 5+) support is effective in facilitating heart recovery, overall survival, and quality of life. years, 80% male) received Impella 5+ and discharged with heart recovery.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
Authors' commentary: Cardiogenicshock in the setting of severe aortic stenosis. This patient’s severe aortic stenosis (AS) and associated severe cardiogenicshock likely created the ECG pattern, resulting in a very difficult challenge for our inpatient team. If you can use Doppler, then you can diagnose it.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content